Patient Characteristics
| Parameter | Data related to dosimetric dataset |
|---|---|
| Median age at treatment start (y) | 68 |
| Sex | |
| Male | 18 (51) |
| Female | 17 (49) |
| Arterial hypertension | 13 (37) |
| Diabetes | 7 (20) |
| Carcinoid syndrome | 9 (26) |
| Primary tumor site | |
| Small intestine | 27 (77) |
| Pancreas | 5 (14) |
| Rectum | 3 (9) |
| Site of metastases at treatment start | |
| Lymph nodes | 27 (77) |
| Peritoneum | 7 (20) |
| Bone | 12 (34) |
| Liver | 31 (89) |
| Tumor grade | |
| 1 | 6 (17) |
| 2 | 27 (77) |
| 3 | 1 (3) |
| Unknown | 1 (3) |
| Treatment before [177Lu]Lu-DOTATATE | |
| Chemotherapy | 12 (34) |
| Targeted therapy | 14 (40) |
| Radiotherapy | 4 (11) |
| Locoregional liver therapy | 15 (43) |
| Somatostatin analogs | 35 (100) |
| Surgery | 11 (48) |
| Previous PRRT with [177Lu]Lu-DOTATATE | 2 (6) |
| At least 1 treatment before [177Lu]Lu-DOTATATE | 35 (100) |
| Markers of progression | |
| Clinical | 14 (40) |
| Biologic | 20 (59) |
| Radiologic | 29 (83) |
Data are number and percentage, except for age.